Canadian DIN & Molecule SearchMolecules A–ZDrug ShortagesResourcesHealth Canada WeeklyRequest a Quote

ZEVTERA 500 MG / VIAL — DIN 02446685

ZEVTERA · AVIR PHARMA INC. · wholesale supply in Canada

Health Canada status: MARKETED

ZEVTERA 500 MG / VIAL  - DIN 02446685
ZEVTERA — DIN 02446685. Product photograph held by Nexara Health.

What is ZEVTERA?

ZEVTERA 500 MG / VIAL contains ZEVTERA. It is listed in the Health Canada Drug Product Database under DIN 02446685, held by AVIR PHARMA INC.. Health Canada currently lists it as marketed, status dated 20-Mar-2018. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.

What is ZEVTERA used for?

Treatment of hospital-acquired pneumonia (HAP), excluding ventilator-associated pneumonia (VAP), and community-acquired pneumonia (CAP) caused by susceptible strains of designated microorganisms in patients 18 years of age and older.

Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.

How is it supplied and stored?

Pack configuration, storage class and the handling constraints that drive cold-chain planning. One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced.

Strength on the label500 MG / VIAL
Pack configuration (monograph)20 mL clear type I glass vials fitted with a grey butyl closure and an aluminum seal with a blue plastic flip-off cap. A carton contains 10 vials.
StorageThe reconstituted solution can be stored at room temperature for up to 1 hour, or in a refrigerator for up to 24 hours.
Shipping classCold chain — validated shipper with temperature monitoring

Before an order line is unambiguous Nexara needs the strength, the pack size and the presentation, because this listing covers more than one of them.

Cold chain. This product is stored refrigerated. Nexara ships it on a validated cold chain with temperature monitoring; a delivery address that cannot receive and store it at 2–8 °C on arrival must be flagged before the order is placed.

Confirm the pack and get a price

Health Canada record and identifiers

The regulatory facts straight from the Drug Product Database, plus every identifier form Nexara accepts on a purchase order. A DIN written without its leading zeros is the commonest reason an order line fails to match.

DIN (8-digit, as used in ordering)02446685
DIN (unpadded, as printed on some documents)2446685
Brand nameZEVTERA
Generic / active ingredientZEVTERA
Market authorization holderAVIR PHARMA INC.
Health Canada schedulePRESCRIPTION
Current statusMARKETED
Status date20-Mar-2018
Status sourceLive Health Canada DPD sync

Verify on the primary sources

Health Canada DPD record Approved product monograph (PDF)

How is it administered?

Recommended dose is 500 mg administered as a 2-hour intravenous infusion every 8 hours. Usual treatment duration is 4–14 days for CAP, and 7–14 days for HAP.

Included because it drives pack selection and wastage. Consult the monograph.

Contraindications

Hypersensitivity to ceftobiprole medocaril, any ingredient in the formulation, cephalosporin class of antibacterials, or immediate and severe hypersensitivity to any other beta-lactam antibacterial agent.

Warnings and precautions

Serious and occasionally fatal hypersensitivity (anaphylactic) and severe cutaneous adverse reactions (SCAR) have been reported. Prolonged use may result in overgrowth of non-susceptible organisms.

How can I get it?

Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.

Request a quote for ZEVTERA

Ordering questions

Who can buy this from Nexara?

Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address. Patients and unlicensed buyers are routed to a partner pharmacy.

Is there a minimum order?

Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.

What is the lead time?

Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.

Why is there no price on this page?

Nexara quotes a delivered Canadian price per order, against a verified licence. Foreign list prices are published on incompatible bases and are not a guide to what any buyer can obtain here, so this page shows which markets list the molecule and on what basis, and nothing more.

Can Nexara supply this for a clinical trial?

Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.

Sources and disclaimer

Product data sourced from the Health Canada Drug Product Database and the approved product monograph (PDF). Health Canada status reconciled against the live DPD sync. Last reviewed 10 Sep 2026.

Nothing on this page is medical advice. Nexara Health is a licensed wholesale distributor and supplies licensed entities only; consumer orders are routed to a partner pharmacy. Alternatives tables describe supply, not clinical equivalence.

Health Canada Drug Product Database (DPD), DIN 02446685. Last reviewed 2026-09-10. Nexara Health is a licensed wholesaler and supplies licensed entities only; consumer orders are routed to a partner pharmacy.